Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Citrucel, Metamucil Ads Target Emerging Laxative Market: Low-Carb Dieters

This article was originally published in The Tan Sheet

Executive Summary

GlaxoSmithKline and Procter & Gamble are leveraging the emerging low-carb dieting trend to market their older laxative products to new target populations

You may also be interested in...



Low-Carb Health Consequences Create Supplement Opportunity – Consultant

Dietary supplement makers should leverage the low-carb dieting trend by looking at ingredients for GI health and positioning other products that address the health consequences of a low-carb diet, according to Steve French, marketing partner for the Natural Marketing Institute (NMI)

Low-Carb Health Consequences Create Supplement Opportunity – Consultant

Dietary supplement makers should leverage the low-carb dieting trend by looking at ingredients for GI health and positioning other products that address the health consequences of a low-carb diet, according to Steve French, marketing partner for the Natural Marketing Institute (NMI)

Low-Carb Health Consequences Create Supplement Opportunity – Consultant

Dietary supplement makers should leverage the low-carb dieting trend by looking at ingredients for GI health and positioning other products that address the health consequences of a low-carb diet, according to Steve French, marketing partner for the Natural Marketing Institute (NMI)

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS096656

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel